AN2 Therapeutics (ANTX) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Platform and pipeline overview

• Focus on boron chemistry platform for novel small molecules in infectious diseases and oncology.

• Two drugs previously approved at Anacor; one pending EMA review.

• Pipeline includes epetraborole for NTM lung disease, melioidosis, and Chagas disease, plus novel oncology candidates.

• Oncology programs aim for first- or best-in-class status, with at least one candidate entering development this year.

• Cash runway projected through 2027, supporting ongoing and new programs.

NTM lung disease clinical development

• Epetraborole tested in a seamless Phase II-III trial for treatment-refractory MAC lung disease, a high unmet need.

• Phase II showed positive results on primary and key secondary PRO endpoints, with robust clinical signals.

• Patient population was highly refractory, with significant disease burden and multi-drug resistance.

• 97 patients remain blinded in Phase III; plan to unblind and engage FDA for next steps.

• FDA guidance supports clinical PROs as primary endpoints; company confident in regulatory path.

Chagas disease and other infectious disease programs

• Chagas candidate targets a novel, validated mechanism (CPSF3) and enters Phase I this year, Phase II next year.

• Preclinical models show 100% cure in chronic infection; market potential estimated at $500M–$1B annually.

• Phase I data expected to be published; Phase II to start quickly with proof of concept anticipated soon.

• Melioidosis program completed an observational study; new trial to start in H2, funded by NIH.

• Epetraborole to be tested as add-on therapy to reduce mortality in melioidosis.